Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brussels – page 40

2 059 clinical trials in Brussels, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brussels at a glance
2 059
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

2 059 trials in Brussels

Open in trial search

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Cutiss AG

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Sponsor:Global Blood Therapeutics Inc.

Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of Sarilumab for Patients with Rheumatoid Arthritis Not Responding to Anti-TNF Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sarilumab
  • Sponsor:Cliniques Universitaires Saint-Luc

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Prednisone
  • Sponsor:Takeda Development Center Americas Inc.

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Crohn's disease

Recruiting

Study of Mirikizumab for Children with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study of HM15912 for Adults with Short Bowel Syndrome-associated Intestinal Failure

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Hanmi Pharm. Co. Ltd.

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brussels

What the registry says about research in the country

01 Oncology

In Bruxelles, several trials focus on neoplasms, especially breast cancer, colorectal cancer, lung cancer, glioblastoma, soft tissue sarcoma, and other advanced solid tumors. These studies are designed to test new treatment combinations, improve survival outcomes, and refine more personalized care for people with difficult-to-treat cancers.

  • ER-positive, HER2-negative breast cancer and related high-risk disease
  • EGFR-mutated non-small cell lung cancer and metastatic lung disease
  • Glioblastoma and other advanced brain tumors
  • Colon cancer, rectal cancer with liver metastasis, and broader advanced solid tumors

Much of this research aims to evaluate whether new therapeutic approaches can better control tumor growth and extend disease-free or overall survival.

02 Neurology and Stroke Care

Clinical trial activity in Bruxelles also includes nervous system diseases, with a strong focus on acute ischemic stroke and intracerebral haemorrhage. The main goal is to improve recovery after stroke and assess safer, more effective treatment strategies in urgent care settings.

  • Acute ischemic stroke with incomplete reperfusion
  • Stroke in patients with recent direct oral anticoagulant use
  • Intracerebral haemorrhage and prevention of later vascular events

These studies are centered on improving functional outcomes, supporting better reperfusion, and understanding how to optimize care after a stroke.

03 Respiratory and Critical Care Medicine

Research in respiratory tract diseases is active, particularly for pneumonia and severe infections requiring hospital or intensive care support. The trials are examining ways to reduce complications, improve recovery, and measure whether new add-on treatments can make standard care more effective.

  • Severe community-acquired pneumonia
  • Hospital-acquired pneumonia
  • Severe pneumonia in critically ill patients

This area includes efforts to test supportive treatments that may help improve survival and shorten the time patients spend in hospital.

04 Cardiovascular and Acute Care Research

Trials in cardiovascular diseases are studying conditions such as cardiogenic shock and other severe acute cardiac or circulatory emergencies. The research is focused on evaluating treatment effectiveness and safety in life-threatening situations where rapid decision-making is essential.

  • Cardiogenic shock linked to acute coronary syndrome
  • Cardiogenic shock of septic origin
  • Cardiogenic shock due to acute decompensated heart failure

These studies aim to provide reliable evidence on outcomes such as mortality and time to hospital discharge.

05 Dermatology and Viral Infections

A distinct group of studies addresses immune system diseases and virus diseases, with work on psoriasis, human papillomavirus, Epstein-Barr virus, and non genital warts. The research is designed to assess symptom improvement, infection clearance, and the longer-term safety of treatment options.

  • Moderate to severe plaque psoriasis
  • HPV infection and genital wart disease
  • Epstein-Barr virus infection
  • Non genital warts

These trials reflect a mix of symptom-focused and infection-focused research in common yet persistent conditions.

06 Infectious Disease and Antiviral Research

Bruxelles is also hosting studies in bacterial infections and mycoses as well as chronic viral disease, including HIV. The emphasis is on improving clinical outcomes, supporting recovery, and testing therapies that may better control infection-related complications.

  • HIV in patients with suppressed viral load
  • Hospital-acquired and severe respiratory infections
  • Viral and skin infections associated with HPV and EBV

This area combines prevention, symptom control, and treatment-response research across several infection types.

07 Breast Cancer and Personalized Treatment

Several trials are specifically focused on breast cancer, including early-stage, locally advanced, and metastatic disease. The research explores more individualized treatment strategies, including approaches guided by tumor biology and relapse risk.

  • ER-positive, HER2-negative breast carcinoma
  • Premenopausal high-risk HR-positive breast cancer
  • High-risk relapse after initial breast cancer treatment

These studies are intended to help match treatment intensity more closely to a patient’s risk profile and tumor characteristics.

08 Gastrointestinal Oncology

Research in digestive system diseases includes studies of colon cancer and rectal cancer, with special attention to older adults and patients with higher recurrence risk. The main goal is to compare treatment strategies that may improve long-term cancer control.

  • Stage III colon cancer
  • Upper rectal cancer
  • Colon and rectal cancer with liver metastasis

This work explores how postoperative treatment choices can support better relapse-free survival and overall disease management.

09 Metabolic and Autoimmune-Related Treatment Safety

Another research stream addresses longer-term treatment safety in immune system diseases, especially for chronic inflammatory conditions. In the city of Bruxelles, investigators are comparing whether newer therapies can maintain effectiveness while reducing health risks over time.

  • Moderate-to-severe plaque psoriasis
  • Cardiovascular safety in long-term treatment use
  • Comparative treatment safety in chronic inflammatory disease

These trials are aimed at supporting safer long-term management for people living with chronic conditions.

10 Not Otherwise Specified / Mixed Oncology Research

Some trials cannot be neatly placed into a single therapeutic category, but they still contribute to the broader oncology and clinical research landscape. These studies often focus on evaluating new treatment options for patients with limited standard choices.

  • Participants with advanced solid tumors
  • Metastatic or advanced cancer populations
  • Recurrent glioblastoma and other hard-to-treat disease settings

The common aim is to test whether emerging therapies can offer meaningful benefit where current options remain limited.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.